Skip to main content
Top
Published in: Strahlentherapie und Onkologie 2/2017

01-02-2017 | Original Article

Patient’s quality of life after high-dose radiation therapy for thoracic carcinomas

Changes over time and influence on clinical outcome

Authors: Christina Schröder, Prof. Dr. med. Rita Engenhart-Cabillic, Prof. Dr. med Dipl.-Phys. Hilke Vorwerk, Dr. med. Michael Schmidt, Dr. med. Winfried Huhnt, Dr. rer. nat. Eyck Blank, Dr. rer nat. Dietrich Sidow, Dr. med. André Buchali

Published in: Strahlentherapie und Onkologie | Issue 2/2017

Login to get access

Abstract

Purpose

Quality of life (QoL) is an important factor in patient care. This analysis is focused on QoL before and after radio(chemo)therapy in patients with thoracic carcinomas, as well as on its influence on clinical follow-up and survival, and the correlation with treatment-related toxicities.

Materials and methods

The analysis included 81 patients with intrathoracic carcinoma receiving radio(chemo)therapy. For analysis of QoL, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the lung cancer-specific supplement (EORTC QLQ-LC13) were used. QoL data were collected before radiation treatment (RT), and 6 weeks, 12 weeks, 6 months, and 12 months after RT. Other factors were additionally analyzed, including clinical outcome, survival, and side effects.

Results

The functional scales showed maximum values or at least a recovery 12 weeks after RT. Symptoms with a high mean symptom score (> 40) at all appointments were fatigue, dyspnea, and coughing. Insomnia, peripheral neuropathy, appetite loss, dyspnea (from QLQ-LC13), and all pain parameters had an intermediate mean score (10–40). There were low mean scores of < 10 for nausea and vomiting, diarrhea, sore mouth, and hemoptysis. There was a significant correlation between clinical dysphagia and radiation pneumonitis with the associated symptom scales. None of the QoL scores had a significant influence on local and distant control or survival.

Conclusion

12 weeks after RT the QLQ-C30 functional scales show the highest scores or at least a temporary recovery. The symptom scales accurately reflect the common symptoms and treatment-related toxicities. QoL did not prove to be a significant predictor for local and distant control or survival.
Literature
1.
go back to reference Derogar M, Lagergren P (2012) Health-related quality of life among 5‑year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol 30(4):413–418CrossRefPubMed Derogar M, Lagergren P (2012) Health-related quality of life among 5‑year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol 30(4):413–418CrossRefPubMed
2.
go back to reference Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM et al (2012) Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol 30(13):1498–1504CrossRefPubMedPubMedCentral Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM et al (2012) Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol 30(13):1498–1504CrossRefPubMedPubMedCentral
3.
go back to reference Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N et al (2009) Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 27(34):5816–5822CrossRefPubMedPubMedCentral Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N et al (2009) Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 27(34):5816–5822CrossRefPubMedPubMedCentral
4.
go back to reference Rumpold T, Lütgendorf-Caucig C, Jagsch R, Dieckmann K, Watzke H, Pötter R et al (2015) Information preferences regarding cure rates and prognosis of Austrian patients with advanced lung cancer. Strahlenther Onkol 191(7):549–556CrossRefPubMed Rumpold T, Lütgendorf-Caucig C, Jagsch R, Dieckmann K, Watzke H, Pötter R et al (2015) Information preferences regarding cure rates and prognosis of Austrian patients with advanced lung cancer. Strahlenther Onkol 191(7):549–556CrossRefPubMed
5.
go back to reference Tribius S, Raguse M, Voigt C, Münscher A, Gröbe A, Petersen C et al (2015) Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: Results of a prospective study. Strahlenther Onkol 191(6):501–510CrossRefPubMed Tribius S, Raguse M, Voigt C, Münscher A, Gröbe A, Petersen C et al (2015) Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: Results of a prospective study. Strahlenther Onkol 191(6):501–510CrossRefPubMed
6.
go back to reference Maurer J, Schäfer C, Maurer O, Kölbl O (2012) Anxiety and depression in cancer patients during the course of radiotherapy treatment. Strahlenther Onkol 188(10):940–945CrossRefPubMed Maurer J, Schäfer C, Maurer O, Kölbl O (2012) Anxiety and depression in cancer patients during the course of radiotherapy treatment. Strahlenther Onkol 188(10):940–945CrossRefPubMed
7.
go back to reference Arrieta Ó, Angulo LP, Núñez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martínez-López D et al (2012) Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol 20(6):1941–1948CrossRefPubMed Arrieta Ó, Angulo LP, Núñez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martínez-López D et al (2012) Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol 20(6):1941–1948CrossRefPubMed
8.
go back to reference Akin S, Can G, Aydiner A, Ozdilli K, Durna Z (2010) Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs 14(5):400–409CrossRefPubMed Akin S, Can G, Aydiner A, Ozdilli K, Durna Z (2010) Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs 14(5):400–409CrossRefPubMed
9.
go back to reference Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. BMJ 49(2):227–230 Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. BMJ 49(2):227–230
10.
11.
go back to reference Hallqvist A, Bergman B, Nyman J (2012) Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – pooled results from two prospective clinical trials. Radiother Oncol 104(1):39–44CrossRefPubMed Hallqvist A, Bergman B, Nyman J (2012) Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – pooled results from two prospective clinical trials. Radiother Oncol 104(1):39–44CrossRefPubMed
12.
go back to reference Gupta D, Braun DP, Staren ED (2012) Association between changes in quality of life scores and survival in non-small cell lung cancer patients. Eur J Cancer Care (Engl) 21(5):614–622CrossRef Gupta D, Braun DP, Staren ED (2012) Association between changes in quality of life scores and survival in non-small cell lung cancer patients. Eur J Cancer Care (Engl) 21(5):614–622CrossRef
13.
go back to reference Coates A, Porzsolt F, Osoba D (1997) Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 33(7):1025–1030CrossRefPubMed Coates A, Porzsolt F, Osoba D (1997) Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 33(7):1025–1030CrossRefPubMed
14.
go back to reference Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients. Lung Cancer 31(2–3):233–240CrossRefPubMed Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients. Lung Cancer 31(2–3):233–240CrossRefPubMed
15.
go back to reference Ganz PA, Lee JJ, Siau J (1991) Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67(12):3131–3135CrossRefPubMed Ganz PA, Lee JJ, Siau J (1991) Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67(12):3131–3135CrossRefPubMed
16.
go back to reference Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S et al (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23(28):6865–6872CrossRefPubMed Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S et al (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23(28):6865–6872CrossRefPubMed
17.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed
18.
go back to reference Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30(5):635–642CrossRef Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30(5):635–642CrossRef
19.
go back to reference Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 Scoring Manual, 3rd edn. Published by: European Organisation for Research and Treatment of Cancer, Brussels. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 Scoring Manual, 3rd edn. Published by: European Organisation for Research and Treatment of Cancer, Brussels.
20.
go back to reference Schröder C, Blank E, Sidow D, Engenhart-Cabillic R, Buchali A (2015) Is there a future for 74 Gy radiation treatment of NSCLC after RTOG 0617? A comparison of the RTOG study results with our own department’s 74 Gy NSCLC cohort. J Cancer Ther 06(08):642–647CrossRef Schröder C, Blank E, Sidow D, Engenhart-Cabillic R, Buchali A (2015) Is there a future for 74 Gy radiation treatment of NSCLC after RTOG 0617? A comparison of the RTOG study results with our own department’s 74 Gy NSCLC cohort. J Cancer Ther 06(08):642–647CrossRef
Metadata
Title
Patient’s quality of life after high-dose radiation therapy for thoracic carcinomas
Changes over time and influence on clinical outcome
Authors
Christina Schröder
Prof. Dr. med. Rita Engenhart-Cabillic
Prof. Dr. med Dipl.-Phys. Hilke Vorwerk
Dr. med. Michael Schmidt
Dr. med. Winfried Huhnt
Dr. rer. nat. Eyck Blank
Dr. rer nat. Dietrich Sidow
Dr. med. André Buchali
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 2/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-1068-7

Other articles of this Issue 2/2017

Strahlentherapie und Onkologie 2/2017 Go to the issue